

**Citation for published version:**

Chiappini S., and Schifano F., 'Is There a Potential of Misuse for Quetiapine?: Literature Review and Analysis of the European Medicines Agency/European Medicines Agency Adverse Drug Reactions' Database', *Journal of Clinical Psychopharmacology*, Vol. 38 (1): 72-79, February 2018.

**DOI:**

<https://doi.org/10.1097/JCP.0000000000000814>.

**Document Version:**

This is the Accepted Manuscript version.

The version in the University of Hertfordshire Research Archive may differ from the final published version.

**Copyright and Reuse:**

© 2018 Wolters Kluwer Health, Inc.

This manuscript version is made available under the terms of the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Enquiries**

If you believe this document infringes copyright, please contact the Research & Scholarly Communications Team at [rsc@herts.ac.uk](mailto:rsc@herts.ac.uk)

**Is there a potential of misuse for quetiapine? Literature review and analysis of the European Medicines Agency/EMA Adverse Drug Reactions' database**

Stefania Chiappini, MD \*, \*\*, Fabrizio Schifano, MD, FRCPsych \*

\* Casa di Cura Villa Rosa, Viterbo (VT), Italy

\*\* Psychopharmacology; Drug Misuse; and Novel Psychoactive Substances Research Unit; School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK

**Address for correspondence:**

Stefania Chiappini, MD  
Casa di Cura Villa Rosa,  
Via Francesco Baracca 21  
01100 Viterbo (VT), Italy  
stefaniachiappini9@gmail.com

**Key words:** quetiapine; olanzapine; drug misuse; European Medicines Agency; pharmacovigilance

## ABSTRACT

**Purpose/Background:** A recent years' increase in both prescribing and availability of second generation antipsychotics (SGAs) has been observed. According to the literature, typically made up by case studies/series, quetiapine appears to be the most commonly misused SGA, with both intranasal and intravenous intake modalities having been described. Another SGA which has been anecdotally reported to be misused is olanzapine. For these molecules, both a previous history of drug misuse and being an inmate have been described as factors associated with misuse. Hence, whilst providing here an updated literature review of the topic, we aimed here at assessing all cases of quetiapine misuse/abuse/dependence/withdrawal as reported to the EMA's EudraVigilance (EV) database; this was carried out in comparison with the reference drug olanzapine.

**Methods:** All spontaneous, EMA database, reports relating to both quetiapine (2005-2016) and olanzapine (2004-2016) misuse/abuse/dependence/withdrawal issues were retrieved and a descriptive analysis was performed.

**Results:** From the EV database, 18,112 (8.64% of 209,571), and 4,178 (7.58% of 55,100) adverse drug reaction (ADR) reports of misuse/abuse/dependence/withdrawal were, respectively, associated with quetiapine and olanzapine. The resulting PRR values suggested that the misuse/abuse-; dependence-; and withdrawal-related ADRs were more frequently reported for quetiapine (respectively, 1.07; 1.01; and 5.25) in comparison with olanzapine.

**Conclusions:** Despite data collection limitations, present EV data may suggest that, at least in comparison with olanzapine, quetiapine misuse may be a cause for concern.

**Key words:** quetiapine; olanzapine; drug misuse; European Medicines Agency; pharmacovigilance

## Introduction

The intentional misuse of prescribing medications [1] typically involves benzodiazepines; gabapentinoids [2]; opioids; anticholinergics [3]; a range of stimulants [4]; and the selective noradrenalin receptor inhibitors/SNRIs antidepressants [5]. Furthermore, the selective serotonin reuptake inhibitors/SSRIs have been reported to be associated with a risk of both an early and late onset [6] occurrence of withdrawal syndrome [7] (for a thorough review, see [8]). Conversely, there are only a few studies relating to the second generation antipsychotics' (SGA) potential of misuse and withdrawal. Currently, the most popular SGAs medications include aripiprazole, asenapine, clozapine, olanzapine, quetiapine and risperidone. Whilst being associated with a decreased risk of neuroleptic malignant syndrome and extrapyramidal symptoms, SGAs are considered safer than typical antipsychotics. Hence, a related SGAs' increase in prescribing, and hence availability, has recently been reported [9-10]. However, according to the updated (July 2017) PubMed/Medline/Embase literature review here carried out, only specific SGAs, e.g. quetiapine and olanzapine, have emerged as increasingly being misused [1; 3-4]; the following represents an overview of most significant related findings.

### *Quetiapine and olanzapine; overview of clinical pharmacological and misusing issues*

When prescribed, quetiapine is administered in the 400-800 mg/day range for the treatment of schizophrenia; bipolar disorder; and as an add-on in major depression [11], with extensive off label use in anxiety and insomnia. Quetiapine may also be prescribed to treat withdrawal symptoms from abused substances (i.e., alcohol, cocaine, benzodiazepines, or opiates/opioids) whilst alleviating mood symptoms and anxiety [12-14]. However, quetiapine appears to be the most documented abusing SGA; it is anecdotally known as 'Susie Q'; 'Quell'; and 'baby heroin' [13-15], with 'Q ball' and 'Maq ball' being a combination with cocaine [14], or marijuana [16], respectively. Crushed quetiapine tablets can be self-administered through nasal insufflation [17-21], although both oral [13; 22; 23-26], and intravenous routes of administration [13; 19; 27] have been reported. Consistent with these anecdotal clinical observations, post-marketing surveillance reports indicate an increase in quetiapine availability on the black-market [13; 18; 25; 28-29]. Furthermore,

quetiapine, either on its own or in combination with substances such as heroin and/or alcohol [30], is consistently associated with high rates of ambulance attendances, indicating rising community-level harms and greater harm relative to other atypical antipsychotics [31]. Indeed, quetiapine-related emergency department/ED visits increased in the USA by 90% between 2005 and 2011, from 35,581 ED to 67,497 attendances [32]. A 2005-2011 US, general population, National Poison Data System (NPDS) retrospective study on single substance quetiapine exposures [33] identified 3,116 cases of either misuse or abuse, which was more common in adolescents and with a moderate/major toxicity occurring in about 1 out of 4 cases. A more recent (e.g. 2003-2013) NPDS database retrospective analysis, identifying all cases of single-substance second-generation antipsychotic exposures coded as 'intentional abuse', was carried out [34]. During this 10-year period, some 2,118 cases of quetiapine, and 1,379 cases of remaining SGAs', abuse were identified. After quetiapine (representing 60.6% of all abuse cases during the study period), the next most frequently abused molecules were risperidone (530 cases, 15.2%) and olanzapine (246 cases, 7.0%). Among quetiapine cases, some 40.8% were treated and discharged, 10.3% admitted to critical care, and 7.2% admitted to a psychiatric facility.

Data from specific sub-populations provide further insights. Anecdotal reports indicate an increase in misusing levels in prison settings [13-14; 22; 35; 19], where recreational drugs are less readily available and quetiapine anxiolytic/sedative properties may be putatively helpful to cope with drug withdrawal [13]. McLarnon et al [36] examined quetiapine misuse among clients from a community-based methadone maintenance program, and found that 80% of participants reported a lifetime quetiapine use; of these, 21% reported taking quetiapine exclusively without a prescription. Malekshahi et al [37] screened some 429 addict inpatients and found that 73 (17%) reported levels of antipsychotic, and especially quetiapine (96% of cases), misuse which was carried out to enhance and/or counteract the remaining psychotropics' effects [17; 19; 21; 27; 38]. There may be no straightforward pharmacological explanations for non-medicinal quetiapine abuse. Overall, the recreational drugs' 'high' has been associated with increased levels of dopamine in the nucleus accumbens (NAc) shell/mesolimbic areas [15] and, similar to remaining antipsychotics, quetiapine blocks dopamine D2 receptors [16]. However, quetiapine, but not olanzapine, may

increase DA levels [39], preferentially in the NAc shell [40], with some data [41] suggesting as well a quetiapine-associated enhancement of cocaine reinforcing potency. Conversely, mechanisms like fast dissociation from dopamine receptors [12; 42-43]; and prefrontal dopamine release mediated by 5-HT<sub>1A</sub> receptor activation and 5-HT<sub>2A</sub> inhibition [44], putatively explaining some recreational effects, are shared by other, non-misusing, SGAs [45]. Hence, there may be other factors [46-47] or pharmacological effects which may be behind the molecule misusing potential. These effects may include: norquetiapine-related norepinephrine reuptake blockade [13]; 5HT<sub>7</sub> antagonist properties [16]; and sigma receptors' activation [48-49]. Some pharmacokinetics' issues have been suggested to represent important issues as well in facilitating quetiapine misuse [50]. In fact, as quetiapine metabolism is mediated by the human cytochrome CYP3A4, a pharmacokinetic interaction may occur with a variety of drugs, including analgesics, anti-arrhythmia, antibiotics, anticonvulsants, antihistamines, antiparkinsonians, pump inhibitors, steroids, and triptans [50]. Furthermore, the high plasma concentrations of free testosterone in male subjects may contribute to higher CYP3A4 activity, which may be associated with a faster biotransformation of quetiapine, [50] and hence a possible tendency to increase its dosage, in males. Both quetiapine XR and IR formulations are generally well tolerated. However, with respect to the IR one, the XR formulation presents with a delayed (e.g. by approximately 3 hours) and blunted (e.g. by approximately 67%) serum peak, features that may contrast the occurrence of the drug-related 'rush', hence making it less attractive to abusers [28]. Furthermore, the XR formulation coating may make the crushed tablets' snorting quite problematic [29].

Olanzapine, at 5-20mg oral daily dosages, is prescribed to treat schizophrenia, bipolar disorder, and resistant depression [30]. Due to its relaxing/anxiolytic activity [54], olanzapine ('Lilly') has been anecdotally advised, at daily dosages of up to 50mg, as the 'ideal trip terminator/modulator' after a psychedelic drug binge. Valeriani et al [55] carried out a range of exploratory qualitative searches of 163 discussion fora/specialized websites, and found that misusers may ingest olanzapine to treat unwanted 'comedown' symptoms (depression, dysphoria, anxiety, and insomnia) from drug/alcohol intake [56], although olanzapine withdrawal symptoms have been described as well [37; 54]. More recently, it was assessed the prevalence of olanzapine misuse among adult patients

on methadone maintenance treatment attending the National Drug Treatment Centre (NDTC) in Dublin. Out of 92 participating clients, some 30% reported a lifetime history of non-medical use of olanzapine, with 9 people (10%) having reported daily dosages of 30 mg or higher and 3 people (3%) typically ingesting 100 mg. Although the most common reasons for self-administration were to cope with anxiety and sleeping disturbances, a quarter used olanzapine to 'get stoned' [57].

The neuro-pharmacological issues behind olanzapine misuse/self-medication potential may be associated, *per se*, with its anxiolytic/antipsychotic activity [16]; a 'reshuffling' in GABA(A) receptor subtypes over time [58]; and the rewarding glutamatergic stimulation of the ventral tegmental area dopaminergic neurons [55]. It is of further interest that both quetiapine [59] and olanzapine [60] present with different degrees of 5HT<sub>2C</sub> and histamine/H1 antagonist properties [22; 60-61]. Finally, quetiapine, clozapine, and olanzapine are unique among SGAs, since they possess levels of anticholinergic activity, a pharmacological element which has been associated with a misusing potential [62]. However, olanzapine and clozapine are much more potent than quetiapine at inhibiting the muscarinic M1 receptors [60].

One could tentatively hypothesize that quetiapine and olanzapine are being misused in different ways and/or for different reasons. Both drugs may indeed be self-administered to cope with either anxiety/sleep disturbances and/or with remaining recreational drugs' withdrawal symptoms. However, whilst olanzapine may be ingested/misused to self-medicate the psychopathological issues associated with remaining recreational drugs' intake [55], quetiapine might possess peculiar levels of recreational value as well, which may increase its addictive liability levels [3].

According to the Prescription Cost Analysis (PCA) system [63], the total prescription items dispensed (any formulations) in England for quetiapine (2005-July 2016) and olanzapine (2004-July 2016) were respectively 21,171 and 23,025 thousands. In the same time frame, according to the Drug Analysis Profiles of the Yellow Card Scheme [64], some 2,344 ADRs were reported in the UK for quetiapine; out of these, 32 ADRs were classified as 'drug dependence/drug withdrawal/drug abuse'. In the case of olanzapine, the total number of ADRs reported was 3,452; out of these, 31 ADRs were classified as 'drug dependence/drug withdrawal/drug abuse'. Hence, at least in the UK and in comparison with olanzapine, quetiapine resulted to be: slightly less frequently prescribed;

and associated with a smaller total number of general, and hence a comparatively higher number, of abuse/dependence/withdrawal ADRs' reports. According to the 2015 Norwegian Prescription Database, antipsychotic-related, sales' figures, the pattern of quetiapine dispensing in Norway was likely to reflect a predominant off-label use of the molecule, although the paper however made no mention of olanzapine data [65]. Similarly, the national OPPIDUM French addictovigilance network has highlighted emerging behaviour of abuse, including prescribing opioids, pregabalin and quetiapine [66].

To better understand the issue of quetiapine abuse, as opposed to the reference drug olanzapine, we aimed here at analyzing the European Medicines Agency (EMA) EudraVigilance (EV) database [67], which collects electronic reports of suspected adverse drug reactions (ADRs) for all medicinal products authorized in the European Economic Area/EEA.

## **Methods**

The EMA (e.g. the Agency responsible for the safety monitoring of medicines developed for use in the European Union-EU) EV database, focusing on case reports submitted, up to mid-July 2016, of quetiapine and olanzapine misuse-/abuse-/dependence- and withdrawal-related ADRs, was here assessed. The ADRs here considered were, per se, spontaneous, unsolicited, communications [68] reported by both Regulatory Authorities of the Member States where the reaction occurred, and/or by the Marketing Authorization Holders for those ADRs occurring outside the EEA.

Search periods for quetiapine and olanzapine differed, since they presented with different approval/commercial availability times; for a thorough description of the EV database refer to [2]. Within the standardized MedDRA Query (SMQ) 'drug abuse, dependence and withdrawal' section [69], we identified the following adverse reactions associated with quetiapine and olanzapine: 'dependence', 'drug abuse', 'drug dependence', 'drug withdrawal syndrome', 'intentional product misuse', 'substance abuse', 'substance dependence', and 'withdrawal syndrome'. 'Misuse' was here meant to be the 'intentional and inappropriate use of a product other than as prescribed or not in accordance with the authorized product information'. Conversely, 'abuse' was here defined as the 'intentional non-therapeutic use of a product for a perceived reward or desired non-therapeutic

effect including, but not limited to, getting high/euphoria'. The term 'addiction', typically replaced by 'dependence' [70], is the 'overwhelming desire to take a drug for non-therapeutic purposes together with the inability to control or stop its use despite harmful consequences'. Finally, 'withdrawal' is here defined as: 'a substance-specific syndrome which follows cessation or reduction in the intake of a psychoactive substance previously regularly used' [71]. ADRs' numbers differed from those referring to case reports, since different reporters/senders could have independently flagged the same ADR to EMA. Each individual patient in the database has a code (EV local number) for identification. Hence, the number of individual patients was unequivocally identified. To more properly compare quetiapine with olanzapine, the proportional reporting ratio (PRR) approach was here considered, and defined as: 'the ratio between the frequency with which a specific adverse event is reported for the drug of interest (relative to all adverse events reported for the drug) and the frequency with which the same adverse event is reported for the drug(s) in the comparison group (relative to all adverse events for drugs in the comparison group' [72]). Being a measure of disproportionality, a PRR greater than 1 suggests that the adverse event is more commonly reported for individuals taking the drug of interest relative to the comparison drug(s) (see also [2]). The PRR is computed as follows:

$$\frac{W/W+X}{Y/Y+Z}$$

(where: W=number of quetiapine cases relating to the chosen adverse event(s); X=number of quetiapine cases involving any other adverse events; Y=number of olanzapine cases relating to the chosen adverse event(s); and Z=number of olanzapine cases involving any other adverse events (for a thorough description of both the PRR approach and the ethical issues relating to the EV database data storage, please refer to [2]).

## **Results**

### *Quetiapine ADRs*

Over the period 07/2005–07/2016, EMA received 209,571 ADRs reports relating to quetiapine (see Table 2); of these, 18,112 reports were relating to misuse/abuse/dependence/withdrawal issues,

corresponding to 884 patients, and 8.64% of all ADRs recorded. Most (87.21%) patients were in the 18-64 years old age-range, whilst 2.1% were in the 9-18 years old age-range. The number of reports increased consistently year-per-year, with a peak in 2009 (85,169 reports) and a decrease in 2014 (6,180 reports), reaching 2,062 by July 2016 (see Fig. 1). Using the SMQ terms, most frequently reported ADRs were classified as 'drug abuse' (52.21%), 'drug dependence' (26.43%), and 'substance abuse' (7.6%). In the sample, male adults were more represented (F/M ratio=0.96), however an overall female majority (F/M ratio: 1.22) was identified in the total number of ADRs' reports. The index drugs reported to be mostly misused in combination with quetiapine included antidepressants (identified in n=415/884, e.g. 46.9% of cases, with citalopram, trazodone and sertraline being those most typically reported); benzodiazepines (identified in n=392; 44.3%); and opiates/opioids (identified in n=383; 43.3%). The precise quetiapine dosage associated with the ADRs of interest was reported in only a minority of cases (e.g. 259 out of 884 patients). In 106 cases, quetiapine resulted to be prescribed in the dosage-range of 25-200 mg, whilst in 43 cases the dosages ingested exceeded the daily maximum therapeutic amount of 800 mg, with 19 grams being the highest level being reported. Although information on the formulations of quetiapine (e.g. extended/XR vs immediate-release/IR) associated with the above ADRs were available for only a minority of reports (e.g. n=2,265), the IR preparations were here involved on most cases (n=2,122; 93.7%). Finally, 22 cases of quetiapine nasal insufflation, and 18 cases of parenteral/intravenous intake, were here described.

### *Olanzapine ADRs*

Over the period 09/2004–07/2016, EMA received 55,100 ADR reports relating to olanzapine (see Table 2). Of these, 4,178 were relating to misuse/abuse/dependence/withdrawal issues, corresponding to 237 patients and 7.58% of all ADRs recorded. Most (71.6%) patients were in the 18-64 years old age-range, whilst 2.15% were in the 9-18 years old age-range. The number of reports showed a peak in 2012 (ADRs number: 1,158; see Fig. 2). Using the SMQ terms, most frequently reported ADRs were classified as 'drug abuse' (55.43%) and 'drug dependence' (29.94%). Most subjects involved were male adults (F/M ratio: 0.96), and the same gender distribution was

seen as well in all ADRs' reports (F/M ratio: 0.84). Index drugs reported to be mostly misused in combination with olanzapine included antidepressants (identified in n=114, e.g. 48.1% of cases, with sertraline, fluoxetine and trazodone being those most typically reported); benzodiazepines (identified in n=104; 43.9%); and opiates/opioids (identified in n=82; 35.9%).

The precise olanzapine dosage associated with the ADRs of interest was reported in only a minority of cases (e.g. 115 out of 237 patients); in 19 cases (16.5%) olanzapine resulted to be prescribed at a dosage below 5 mg. Conversely, in 37 cases (32.2%) the dosage ingested exceeded indeed the daily maximum therapeutic amount of 20 mg, with 11 grams being the highest level reported. Finally, 1 case of olanzapine nasal insufflation, and 7 cases of parenteral/intravenous intake were here described.

#### *Quetiapine versus olanzapine; PRR Computation*

The 'quetiapine versus olanzapine' PRR values were calculated whilst considering the most represented ADRs' categories (e.g. a) intentional product misuse; drug abuse; and substance abuse; b) drug dependence; and substance dependence; and c) withdrawal syndrome; and drug withdrawal). The resulting PRR values suggested that the misuse/abuse-; dependence-; and withdrawal-related ADRs were more frequently reported for quetiapine (respectively, 1.07; 1.01; and 5.25) in comparison with olanzapine (see Table 1).

#### *Related Fatalities*

In the 884-patient quetiapine misuse/abuse/dependence/withdrawal group (18,112 ADRs), 368 (45.2%; 2,979 ADRs) fatalities were identified, but only in 5 cases the drug was reported on its own. Conversely, in the 237-patient olanzapine misuse/abuse/dependence/withdrawal group (4,178 ADRs), 79 (34.6%; 687 ADRs) fatalities were identified, and only in 1 case olanzapine was reported on its own. For both quetiapine and olanzapine, most fatalities involved female adults; had occurred in non-EEA countries; and had been reported by pharmaceutical companies.

In association with both quetiapine and olanzapine fatalities, antidepressants, opiates/opioids, and benzodiazepines were the concomitant drugs most typically identified. A range of recreational substances (e.g. alcohol, amphetamines, cannabis, and ketamine) was at times identified as well.

## **Discussion**

To the best of our knowledge, this is the first study aimed at systematically identifying and analyzing quetiapine-, as opposed to olanzapine-, misuse/abuse/dependence/withdrawal issues. Present, large scale, data have been extracted from a pharmacovigilance database, such as the EMA's EV that, together with the World Health Organization's Drug Monitoring Program [73], is considered a worldwide reference standard.

Although the observation period for olanzapine was longer, the selected misuse/abuse/dependence/withdrawal-related ADR reports were more represented in the quetiapine, in comparison with the olanzapine, group; respectively: n=18,112 vs n=4,178. These ADRs showed a peak in 2009 and 2012, respectively, for quetiapine and olanzapine. A consistent proportion of reports were being filed here by the pharmaceutical companies manufacturing the branded products. However, in recent years the generic formulations of both molecules have gradually/partially replaced worldwide the branded formulations; this may somehow explain the recent years' observed reduction in related ADRs' levels. It is of note that most related literature papers, so far, have been based on small case series/single case studies [19; 26; 54]. Conversely, current findings refer to much larger (e.g. 884 vs 237) numbers of patients respectively presenting with either quetiapine or olanzapine misuse/abuse/dependence/withdrawal issues, tentatively suggesting different (e.g. quetiapine higher than olanzapine) addictive liability levels of these molecules. This is consistent with the resulting PRR values, indicating that the misuse/abuse-; and dependence-related ADRs were here more frequently reported (e.g. respectively: 1.07; and 1.01) for quetiapine in comparison with olanzapine. Furthermore, a range of idiosyncratic (e.g. insufflation; parenteral/intravenous) intake modalities were more frequently identified in the quetiapine (n=40) vs olanzapine (n=8) groups. Consistent with previous literature findings [51], the XR formulations were here represented in only a minimal proportion (e.g. 6.3%) of cases.

Overall, most quetiapine and olanzapine ADRs' misuse/abuse/dependence/withdrawal reports involved adult (18-64 years old) males. Although gender distribution issues for bipolar disorder are somehow unclear [74], the finding is consistent with males being more represented both in substance misuse [75]; and schizophrenia [76] disorders. Considering the putative recreational value of these molecules, it is a reason of concern that for both quetiapine and olanzapine some 2% of the abuse/misuse/dependence/withdrawal ADRs involved children/adolescents.

Misuse/abuse/dependence/withdrawal ADRs were here associated, in 1 case out of 6, with supra-therapeutic, or even extraordinarily high, dosages for quetiapine and this occurred even more frequently (eg. 1 case out of 3) for olanzapine. Conversely, however, these ADRs were frequently (e.g. quetiapine: 41%; olanzapine: 16%) reported as well for sub-therapeutic dosages (e.g. up to 200 mg for quetiapine and up to 5 mg for olanzapine). In everyday clinical practice, and this is especially true for quetiapine, these small dosages are frequently prescribed for a range of issues such as insomnia, inner restlessness, and anxiety [12-13]. Thus, the current finding of a potential for both molecules to be associated with misuse/withdrawal issues in such a low dosage-range might be considered of clinical relevance.

Apart from benzodiazepines and opiates/opioids, antidepressants (mostly SSRIs and trazodone) were those drugs most frequently identified in combination with both quetiapine and olanzapine. Indeed, this may suggest the comorbid presence of depression with substance misuse conditions. On the other hand, trazodone prescribing has been advised for the treatment of alcohol-, drug- and benzodiazepine-dependent patients [77]. Although the use of SSRIs for the treatment of addictions is quite controversial [78], it is of interest that, similarly to remaining psychotropics, SSRIs have indeed been associated with the occurrence of a proper withdrawal syndrome [79], and this may have overlapped with the quetiapine and olanzapine withdrawal reporting levels here identified. The quetiapine vs olanzapine withdrawal PRR value (5.25) resulted here to be particularly high. This finding seems to be consistent with a range of literature reports, suggesting both levels of tolerance [26], and the occurrence of a discontinuation/withdrawal syndrome (e.g. craving, insomnia, nausea, sweating, headache, diarrhea, vomiting, dizziness and irritability) following the abrupt cessation of quetiapine intake [13; 25; 61]. Other reports describe as well both

a 'rebound' (e.g. rebound psychosis and rebound insomnia; [80]); and a proper 'withdrawal' syndrome (e.g. tachycardia, insomnia, anxiety, and dysphoria [60]) after discontinuing or switching from olanzapine to another drug. Quetiapine IR preparations, here most typically represented, are short-acting, and therefore more likely to produce a physiological withdrawal reaction than the longer-acting olanzapine. This can occur in people who are taking it as prescribed, as well as those who are 'misusing' it. This may contribute to explaining the substantial withdrawal PRR difference here observed between quetiapine and olanzapine. Unfortunately, however, the EV database did not provide here further details of clinical interest, including: medication dosage prescribed prior to discontinuation; range/intensity of withdrawal symptoms; time-frame of the clinical presentation of withdrawal; and the possible concurrence of psychopathological conditions.

### *Fatalities*

In the EV database 368 quetiapine- and 79 olanzapine-related fatalities were respectively identified. Although this finding is in itself interesting, to be able to calculate properly the related 'fatal toxicity index' [81] the total number of patients exposed to either quetiapine or olanzapine may be needed. Furthermore, most fatalities were here the result of a polydrug intake, including opiates/opioids, and this may well have increased the levels of risk [82; 83].

Quetiapine fatalities have already been described [13; 22-26; 29; 84-85]. Finally, Vance and McIntyre [86] described 28 cases involving olanzapine examined at the San Diego County Medical Examiner's Office during the time-frame 2004–2007, and in only 6 cases olanzapine was identified on its own.

### *Limitations*

Case reports of suspected ADRs alone are rarely sufficient to confirm that a certain effect in a patient has been caused by a specific medicine. The fact that a suspected adverse reaction has been reported does not necessarily mean that the medicine has caused the observed effect, as this could have also been caused by the disease being treated, another illness, or it could be associated

with another medicinal product taken by the patient at the same time. The number of case reports for a particular medicinal product depends *inter alia* on its availability on the market and its extent of use, the nature of the reaction, as well as the public awareness of a safety concern. Hence, comparing the number of case reports between medicines may give a misleading picture of their safety profile. Furthermore, spontaneous reports were likely to reflect here issues relating to prescribed drugs only, whilst these molecules are widely available from rogue websites and, in some countries, over the counter as well [87]. One could argue that there may be major issues in using worldwide, spontaneously reported, adverse effects' data. Furthermore, the comparison here considered between quetiapine and olanzapine may be difficult, since it assumes that these drugs have similar levels of adverse effects other than the misuse/withdrawal effects, whilst the two molecules present with different profiles of adverse effects/AEs [16]. Indeed, consistent with UK prescription data [63] there were here many more ADRs reported for quetiapine than for olanzapine, but it is unclear if this was due to different global prescribing rates. Unfortunately, however, these prescribing figures are not available due to the wide differences in both availability and collection of prescription data around the world. Present data focus on misuse/abuse/dependence and withdrawal, but these are not the same issues. Indeed, the occurrence of a withdrawal syndrome is not an indication, per se, of an index drug possessing a misuse/recreational value. Several ADRs relating to the same patient were here identified. This may have happened because of a range of different sources reporting the same ADR but also because a number of different ADRs may have been reported for the same patient. Report duplications may occur e.g. where a healthcare professional reported the same suspected ADR to both the national regulator and the Marketing Authorization Holder, and both eventually reported the index ADR to the EV. Furthermore, due to the nature of spontaneous reports, not all data fields are provided for all reports. In particular, the subjects' possible psychiatric/drug misuse history was not available, and the abuse/dependence diagnosis was not made in accordance with international classification standards. Furthermore, a PRR exceeding 1 could also reflect sampling variation in the data, reporting errors, biased reporting, multiple reports of the same case or the same patient, or a number of other causes. Spontaneous reports reflect the information as provided to EV by the

source/reporter. Finally, EMA has to ensure that the protection of privacy and integrity of individuals is guaranteed. Hence, certain data elements (e.g. country specific information, nationally authorized products) were here not disclosed.

## **Conclusions**

Despite data collection limitations, and although further studies are clearly needed, both the literature and current EMA data may tentatively suggest that, at least in comparison with olanzapine, quetiapine misuse may be a cause for concern. Whether quetiapine misuse is occurring on a large scale cannot be confirmed from here but, as the EV reports were submitted spontaneously, present figures may only underestimate the magnitude of the problem. Further prospective studies should be encouraged to better assess quetiapine/SGAs' addictive liability levels. Overall, there is the need for increased awareness and education regarding medication abuse, an issue being facilitated by wide online levels of medicines' availability [87]. Healthcare professionals should be vigilant when prescribing any psychotropics, including both antidepressants [88] and antipsychotics, and particularly to inmates and/or to patients with a substance misuse history. Owing to the possibility of diversion, the increasing off-label use of quetiapine should be reduced; the amount of drug prescribed per individual prescription limited; and, if any related misuse issues are being identified, physicians should consider medication tapering [11; 53].

## **Acknowledgements**

We acknowledge the support offered by EMA in providing access to the EV database. The views expressed here are those of the authors and do not necessarily reflect the EMA officers' views. We thank dr Paolo Alcini, Head of Data Standardisation and Analytics-EMA, for assistance with the analysis of our data and his comments on the manuscript. In contributing to this paper, FS was supported in part by grants of the European Commission (Drug Prevention and Information Programme 2014–16, contract no. JUST/2013/DPIP/AG/4823, EU-MADNESS project). Further financial support was provided to FS by the EU Commission-targeted call on cross border law enforcement cooperation in the field of drug trafficking, DG Justice/DG Migrations and Home

Affairs (JUST/2013/ISEC/DRUGS/AG/6429) Project EPS/NPS (Enhancing Police Skills concerning Novel Psychoactive Substances).

### **Conflicts of interest**

Prof. Schifano and Dr. Chiappini declare no conflicts of interest with respect to the content of this manuscript; however, Prof. Schifano is a member of the EMA Psychiatry Advisory Board.

### **References**

1. James J. Dealing with drug-seeking behaviour. *Aust Prescr* 2016; 39: 96-100.
2. Chiappini S, Schifano F: A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database. *CNS Drugs* 2016; 30: 647-654.
3. Schifano F, Orsolini L, Papanti DG, et al. Novel psychoactive substances of interest for psychiatry. *World Psychiatry* 2015; 14: 15–26.
4. Sarker A, O'Connor K, Ginn R, et al. Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter. *Drug Saf* 2016; 39: 231-240.
5. Francesconi G, Orsolini L, Papanti D, et al. Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences. *Hum Psychopharmacol* 2015; 30: 255-261.
6. Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitors discontinuation: a systematic review. *Psychother Psychosom* 2015; 84: 72-81.
7. Cosci F, Guidi J, Balon R, et al. Clinical methodology matters in epidemiology: not all benzodiazepines are the same. *Psychother Psychosom* 2015; 84: 262-264.
8. Chouinard G, Chouinard VA. New classification of selective serotonin reuptake inhibitor withdrawal. *Psychother Psychosom* 2015; 84: 63-71.
9. Bogart GT, Ott CA. Abuse of second-generation antipsychotics: What prescribers need to know. *Curr Psychiatry* 2011; 10: 77-79.
10. HSCIC (Health and Social Care Information Centre). Prescriptions dispensed in the Community. England 2004-14. Available at: <http://content.digital.nhs.uk/catalogue/PUB17644/pres-disp-com-eng-2004-14-rep.pdf> . Accessed February 20, 2017.

11. FDA Seroquel prescribing Information. 2010. Available at: [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2011/020639s049s054lbl.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020639s049s054lbl.pdf) . Accessed February 20, 2017.
12. Terán A, Majadas S, Galan J. Quetiapine in the treatment of sleep disturbances associated with addictive conditions: a retrospective study. *Subst Use Misuse* 2008; 43: 2169-2171.
13. Srivastava A, Patil V, Da Silva Pereira Y. A Case Series of Quetiapine Addiction/Dependence. *Ger J Psychiatr* 2013; 16: 152-155.
14. Kim S, Lee G, Kim E, et al Quetiapine Misuse and Abuse: Is it an Atypical Paradigm of Drug Seeking Behavior? *J Res Pharm Pract.* 2017; 6: 12-15.
15. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. *Proc Natl Acad Sci USA* 1988; 85: 5274-5278.
16. Stahl SM. *Essential Psychopharmacology; Prescriber's Guide*. 5<sup>th</sup> edition; Cambridge University Press, UK, 2014.
17. Waters BM, Joshi KG. Intravenous Quetiapine-Cocaine Use ("Q-Ball"). *Am J Psychiatry* 2007; 164: 173–174.
18. Pierre JM, Shnayder I, Wirshing DA, et al Intranasal quetiapine abuse. *Am J Psychiatry* 2004; 61: 1718.
19. Hussain MZ, Waheed W, Hussain S. Intravenous quetiapine abuse. *Am J Psychiatry* 2005; 162: 1755–1756.
20. George M, Haasz M, Coronado A, et al. Acute dyskinesia, myoclonus, and akathisia in an adolescent male abusing quetiapine via nasal insufflation: a case study. *BMC Pediatr* 2013; 13: 187.
21. Morin AK. Possible intranasal quetiapine misuse. *Am J Health Syst Pharm* 2007; 64: 723–725.
22. Fischer BA, Boggs DL. The role of antihistaminic effects in the misuse of quetiapine: a case report and review of the literature. *Neurosci Biobehav Rev* 2010; 34: 555-558.
23. Reeves RR, Brister JC. Additional evidence of the abuse potential of quetiapine. *S Med J* 2007; 100: 834-836.

24. Paparrigopoulos T, Karaiskos D, Liappas J. Quetiapine: another drug with potential for misuse? A case report. *J Clin Psychiatry* 2008; 69: 162–163.
25. Murphy D, Bailey K, Stone M, et al. Addictive potential of quetiapine. *Am J Psychiatry* 2008; 165: 167.
26. Chen CY, Shiah IS, Lee WK, et al. Dependence on quetiapine in combination with zolpidem and clonazepam in bipolar depression. *Psychiatry Clin Neurosci* 2009; 63: 427–428.
27. Sansone RA, Sansone LA. Is seroquel developing an illicit reputation for misuse/abuse? *Psychiatry (Edgmont)* 2010; 7: 13-16.
28. Peyrière H, Diot C, Eiden C, et al. Abuse Liability of Quetiapine (Xeroquel®): analysis of the literature. *Fundam Clin Pharmacol* 2015; 29: 27-28.
29. Pilgrim JL, Drummer OH. The toxicology and comorbidities of fatal cases involving quetiapine. *Forensic Sci Med Pathol* 2013; 9: 170-176.
30. Haller E, Bogunovic O, Miller M. Atypical antipsychotics new drugs of abuse. American Academy of Addiction Psychiatry (AAAP) 24th Annual Meeting & Symposium, Scottsdale, Arizona: Abstract 16, presented December 7th, 2013.
31. Heilbronn C, Lloyd B, McElwee P, et al. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. *Drug Alcohol Rev* 2013; 32: 405-411.
32. Mattson ME, Albright V, Yoon J, et al. Emergency Department Visits Involving Misuse and Abuse of the Antipsychotic Quetiapine: Results from the Drug Abuse Warning Network (DAWN). *Subst Abuse* 2015; 9: 39–46.
33. Klein-Schwartz W, Schwartz EK, Anderson B. Evaluation of Quetiapine Abuse and Misuse Reported to Poison Centers. *J Addict Med* 2014; 8: 195-198.
34. Klein L, Bangh S, Cole JB. Intentional Recreational Abuse of Quetiapine Compared to Other Second-generation Antipsychotics. *West J Emerg Med* 2017; 18: 243–250.
35. Pinta ER, Taylor RE. Letter to the editor. Quetiapine Addiction? *Am J Psychiatry* 2007; 164: 1.
36. McLarnon ME, Fulton HG, Maclsaac C, et al. Characteristics of quetiapine misuse among clients of a community-based methadone maintenance program. *J Clin Psychopharmacol* 2012; 32: 721-723.


37. Malekshahi T, Tioleco N, Ahmed N, et al. Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse. *J Subst Abuse Treat* 2015; 48: 8-12.
38. Reeves RR, Ladner ME. Letter to the Editor. Potentiation of the effect of Buprenorphine/Naloxone with Gabapentin or Quetiapine. *Am J Psychiatry* 2014; 171: 691.
39. Cha HJ, Lee HA, Ahn JI, et al. Dependence potential of quetiapine: behavioral pharmacology in rodents. *Biomol Ther (Seoul)*. 2013; 21: 307-312.
40. Tanda G, Valentini V, De Luca MA, et al. A systematic microdialysis study of dopamine transmission in the accumbens shell/core and prefrontal cortex after acute antipsychotics. *Psychopharmacol (Berl)* 2015; 232: 1427-1440.
41. Brutcher RE, Nader SH, Nader MA. Evaluation of the reinforcing effect of Quetiapine, alone and in combination with cocaine, in Rhesus monkeys. *J Pharmacol Exp Ther* 2016; 356: 244-50.
42. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. *J Psychiatry Neurosci* 2000; 25: 161-166.
43. Tauscher J, Hussain T, Agid O, et al. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics. *Am J Psych* 2004; 161: 1620-1625.
44. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. *Prog Brain Res* 2008; 172: 199-212.
45. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. *Ann Rev Med* 2001; 52: 503-517.
46. Montebello ME, Brett J. Misuse and Associated Harms of Quetiapine and Other Atypical Antipsychotics. *Curr Top Behav Neurosci* 2017;34:125-139.
47. Navailles S, De Deurwaerdère P. Presynaptic control of serotonin on striatal dopamine function. *Psychopharmacology (Berl)* 2011; 213: 213-242.
48. Kotagale NR, Mendhi SM, Aglawe MM, et al. Evidences for the involvement of sigma receptors in antidepressant like effect of quetiapine in mice. *Eur J Pharmacol* 2013; 702: 180-186.

49. Yasui Y, Su TP. Potential Molecular Mechanisms on the Role of the Sigma-1 Receptor in the Action of Cocaine and Methamphetamine. *J Drug Alcohol Res* 2016 Feb 20;5: pii: 235970.
50. Grabowski K. Quetiapine abuse and dependence: is pharmacokinetics important? *Acta Clin Belg.* 2017; 13: 1.
51. Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. *Curr Med Res Opin* 2013; 29: 813-825.
52. Reccoppa L. Less abuse potential with XR formulation of quetiapine? *Am J Addiction* 2010; 20: 178.
53. FDA Zyprexa prescribing information. 2009. Available at: [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2009/020592s051,021086s030,021253s036lb1.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020592s051,021086s030,021253s036lb1.pdf) . Accessed February 20, 2017.
54. Dahr R, Sidana A, Singh T. Olanzapine Dependence. *German J Psychiatry* 2010; 13: 51-53.
55. Valeriani G, Corazza O, Bersani FS, et al. Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. *Hum Psychopharmacol* 2015; 30: 249-254.
56. Reeves RR: Abuse of olanzapine by substance abusers. *J Psychoactive Drugs* 2007; 39: 297-9.
57. James PD, Fida AS, Konovalov P, et al. Non-medical use of olanzapine by people on methadone treatment *B J Psych Bulletin* 2016; 40: 314-317.
58. Skilbeck KJ, O'Reilly JN, Johnston GA, et al. The effects of antipsychotic drugs on GABAA receptor binding depend on period of drug treatment and binding site examined. *Schizophr Res* 2007; 90: 76-80.
59. Egerton A, Ahmad R, Hirani E, et al. Modulation of striatal dopamine release by 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor antagonists: [<sup>11</sup>C]raclopride PET studies in the rat. *Psychopharmacol (Berl)* 2008; 200: 487-96.
60. Kumsar NA, Erol A. Olanzapine abuse. *Subst Abuse* 2013; 34: 73-74.


61. Piróg-Balcerzak A, Habrat B, Mierzejewski P. Misuse and abuse of quetiapine. *Psychiatr Pol* 2015; 49: 81-93.
62. Schifano F, di Costanzo E. Excessive use of anticholinergic drugs in a sub-sample of Italian schizophrenics. *Int J Clin Pharmacol Ther Toxicol* 1991; 29: 184-186.
63. Prescription Cost Analysis (PCA), 2016. Available at: <http://www.nhsbsa.nhs.uk/PrescriptionServices/3494.aspx>. Accessed July 11, 2017.
64. Drug Analysis Profiles. The Yellow Card Scheme, 2016. Available at: <https://yellowcard.mhra.gov.uk/the-yellow-card-scheme/>. Accessed July 11, 2017.
65. Gjerden P, Bramness JG, Tvette IF, et al. The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004-2015. *Eur J Clin Pharmacol*. 2017; 73: 1173-1179
66. Frauger E, Pochard L, Boucherie Q, et al. le Réseau français d'addictovigilance. Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network. *Therapie* 2017; pii: S0040-5957(17)30042-2.
67. EudraVigilance. European Medicines Agency. 2015. Available at: <https://eudravigilance.ema.europa.eu/human/index.asp> . Accessed February 20, 2017.
68. Heads of Medicines Agency (HMA) and European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). Module VI: management and reporting of adverse reactions to medicinal products 2, Rev 2016. Available at : [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2016/08/WC500211714.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2016/08/WC500211714.pdf) . Accessed February 20, 2017.
69. Medical Dictionary for Adverse Drug Reactions. MedDRA Version 19.0 English. 2016. Available at: [http://www.meddra.org/sites/default/files/guidance/file/intguide\\_19\\_0\\_english.pdf](http://www.meddra.org/sites/default/files/guidance/file/intguide_19_0_english.pdf) . Accessed February 20, 2017.
70. WHO Expert Committee on Addiction-Producing Drugs. Thirteenth report of the WHO Expert Committee. 2016. Available at: [http://apps.who.int/iris/bitstream/10665/40580/1/WHO\\_TRS\\_273.pdf](http://apps.who.int/iris/bitstream/10665/40580/1/WHO_TRS_273.pdf). Accessed February 20, 2017.

71. MedDRA Introductory guide for Standardised MedDRA Queries (SMQs) Version 15.0. 2012. Available at: [http://www.meddra.org/sites/default/files/guidance/file/smq\\_intguide\\_15\\_0\\_english.pdf](http://www.meddra.org/sites/default/files/guidance/file/smq_intguide_15_0_english.pdf) . Accessed February 20, 2017.
72. European Medicines Agency (EMA). Guideline on the use of statistical signal detection methods in the EudraVigilance data analysis system. 2008. Available at: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/Regulatory\\_and\\_procedural\\_guideline/2009/11/WC500011434.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011434.pdf) . Accessed February 20, 2017.
73. WHO's Drug Monitoring Programme 2016. Available at: [http://www.who.int/medicines/areas/quality\\_safety/safety\\_efficacy/National\\_PV\\_Centres\\_Map/en/](http://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/) . Accessed February 20, 2017.
74. Diflorio A, Jones I. Is sex important? Gender differences in bipolar disorder. *Int Rev Psychiatry* 2010; 22: 437-52.
75. Lader D: Drug Misuse. Findings from the 2014/15 Crime Survey for England and Wales Statistical Bulletin 03/15. 2015. Available at: [https://www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/462885/drug-misuse-1415.pdf](https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/462885/drug-misuse-1415.pdf) . Accessed February 20, 2017.
76. McGrath JJ. Variations in the incidence of schizophrenia: data versus dogma. *Schizophr Bull* 2006; 32: 195-197.
77. Funk S. Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone. *Neuropsychopharmacol Hung* 2013; 15: 85-93.
78. Mendelevich VD, Zalmunin KY: Paradoxes of evidence in Russian addiction medicine. *Int J Risk Saf Med* 2015; Suppl 1: S102-3.
79. Fava GA, Gatti A, Belaise C, et al. Withdrawal symptoms after selective serotonin reuptake inhibitors discontinuation: a systematic review. *Psychoter Psychosom* 2015; 84: 72-81.
80. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. *CNS Drugs* 2013; 27: 545-72.

81. Ojampera I, Kriikku P, Vuori E. Fatal toxicity index of medicinal drugs based on a comprehensive toxicology database. *Int J Legal Med* 2016; 130: 1209-1216.
82. Corkery J, Claridge H, Loi B, et al. Drug related deaths in the UK; Annual Report 2013. International Centre for Drug Policy, St George's, University of London (UK), 2014. Available at: <http://www.re-solv.org/wp-content/uploads/2016/02/Drug-related-deaths-in-the-UK-2013.pdf> . Accessed February 20, 2017.
83. Nelson JC, Spyker DA. Morbidity and Mortality Associated With Medications Used in the Treatment of Depression: An Analysis of Cases Reported to U.S. Poison Control Centers, 2000-2014. *Am J Psychiatry* 2017; 174: 438-450.
84. Parker DR, McIntyre IM. Case studies of postmortem quetiapine: therapeutic or toxic concentrations? *J Anal Toxicol* 2005; 29: 407-412.
85. Skov L, Johansen SS, Linnet K. Postmortem Quetiapine Reference Concentrations in Brain and Blood. *J Anal Toxicol* 2015; 39: 557-561.
86. Vance C, McIntyre IM. Postmortem Tissue Concentrations of Olanzapine. *J Anal Toxicol* 2009; 33: 15-26.
87. Orsolini L, Francesconi G, Papanti DG, et al. Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. *Hum Psychopharmacol* 2015; 30: 302-318.
88. Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. *Psychother Psychosom* 2016; 85: 270-288.



**Figure 1: Number of quetiapine misuse/abuse-, dependence-, and withdrawal-related adverse drug reactions (ADRs) during the 2005-2016 time-frame**



**Figure 2: Number of olanzapine misuse/abuse-, dependence-, and withdrawal-related adverse drug reactions (ADRs); 2004-2016**

<b>Quetiapine ADRs</b>	<b>No of ADRs</b>	<b>Proportion of Quetiapine ADRs</b>	<b>Quetiapine vs Olanzapine PRR</b>
Drug abuse (A1)+ Substance abuse (A2)+ Intentional product misuse (A3)	9,457+1,378+395=11,230	11,230/209,571=0.0535	<b>1.07</b>
Drug dependence (A4)+ Dependence (A5) + Substance dependence (A6)	4,788+48+997=5,833	5,833/209,571=0.0278	
Withdrawal syndrome (A7)+ Drug withdrawal syndrome (A8)	246+636=882	882/209,571=0.0042	
Other Adverse Events (B)	191,626	191,626/209,571=0.9143	
Total (A1+A2+A3+A4+A5+A6+A7+A8+B)	209,571	209,571/209,571=1	
<b>Olanzapine ADRs</b>	<b>No of ADRs</b>	<b>Proportion of Olanzapine ADRs</b>	
Drug abuse (C1)+ Substance abuse (C2)+ Intentional product misuse (C3)	2,316+324+106=2,746	2,746/55,100=0.0498	<b>5.25</b>
Drug dependence (C4)+ Dependence (C5) + Substance dependence (C6)	1,251+7+129=1,387	1,387/55,100=0.0251	
Withdrawal syndrome (C7)+ Drug withdrawal syndrome (C8)	35+10=45	45/55,100=0.0008	
Other Adverse Events Olanzapine (D)	49,868	49,868/55,100=0.9050	
Total (C1+C2+C3+C4+C5+C6+C7+C8+D)	55,100	55,100/55,100= 1	

**Table 1: Quetiapine and olanzapine misuse/abuse-; dependence-; and withdrawal-related ADRs' frequency whilst considering all drug adverse events reported**

	<b>QUETIAPINE ADRs</b>	<b>OLANZAPINE ADRs</b>
<b>Time-frame considered</b>	07/2005–07/2016	09/2004–07/2016
<b>Total number of ADRs</b>	209,571	55,100
<b>Misuse-abuse-/dependence-/withdrawal-related ADRs</b>	18,112	4,178
<b>Number of unique patients being reported to the database</b>	884	237
<b>Age range most typically represented</b>	18-64 yy (87.21%)	18-64 yy (71.6%)
<b>ADRs most typically represented</b>	drug abuse (52.21%), drug dependence (26.43%), substance abuse (7.6%)	drug abuse (55.93%), drug dependence (29.94%)
<b>Gender most typically represented</b>	Male (F/M ratio=0.96)	Male (F/M ratio=0.96)
<b>Concomitant drugs most typically represented</b>	Antidepressants (in n=415/884, 46.9% of cases, with citalopram, trazodone and sertraline being those most typically reported); benzodiazepines (in n=392; 44.3%); opiates/opioids (in n=383; 43.3%)	Antidepressants (in n=114/288, 48.1% of cases, with sertraline, fluoxetine and trazodone being those most typically reported); benzodiazepines (in n=104; 43.9%); and opiates/opioids (in n=82; 35.9%)
<b>Fatalities</b>	368 patients	79 patients

**Table 2: Overview of data relating to quetiapine and olanzapine ADRs as reported to the EV database**